These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 2493974)
1. Intrathecal fibrinolytic therapy after subarachnoid hemorrhage: dosage study in a primate model and review of the literature. Findlay JM; Weir BK; Kanamaru K; Grace M; Gordon P; Baughman R; Howarth A Can J Neurol Sci; 1989 Feb; 16(1):28-40. PubMed ID: 2493974 [TBL] [Abstract][Full Text] [Related]
2. Comparison of intrathecal administration of urokinase and tissue plasminogen activator on subarachnoid clot and chronic vasospasm in a primate model. Hariton GB; Findlay JM; Weir BK; Kasuya H; Grace MG; Mielke BW Neurosurgery; 1993 Oct; 33(4):691-6; discussion 696-7. PubMed ID: 8232810 [TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of intrathecal thrombolytic therapy in a primate model of cerebral vasospasm. Findlay JM; Weir BK; Gordon P; Grace M; Baughman R Neurosurgery; 1989 Apr; 24(4):491-8. PubMed ID: 2496328 [TBL] [Abstract][Full Text] [Related]
4. The effect of timing of intrathecal fibrinolytic therapy on cerebral vasospasm in a primate model of subarachnoid hemorrhage. Findlay JM; Weir BK; Kanamaru K; Grace M; Baughman R Neurosurgery; 1990 Feb; 26(2):201-6. PubMed ID: 2106630 [TBL] [Abstract][Full Text] [Related]
5. Effect of intrathecal thrombolytic therapy on subarachnoid clot and chronic vasospasm in a primate model of SAH. Findlay JM; Weir BK; Steinke D; Tanabe T; Gordon P; Grace M J Neurosurg; 1988 Nov; 69(5):723-35. PubMed ID: 3141595 [TBL] [Abstract][Full Text] [Related]
6. Phase I trial of tissue plasminogen activator for the prevention of vasospasm in patients with aneurysmal subarachnoid hemorrhage. Zabramski JM; Spetzler RF; Lee KS; Papadopoulos SM; Bovill E; Zimmerman RS; Bederson JB J Neurosurg; 1991 Aug; 75(2):189-96. PubMed ID: 1906534 [TBL] [Abstract][Full Text] [Related]
7. Effect of intrathecal fibrinolytic therapy on clot lysis and vasospasm in patients with aneurysmal subarachnoid hemorrhage. Ohman J; Servo A; Heiskanen O J Neurosurg; 1991 Aug; 75(2):197-201. PubMed ID: 1906535 [TBL] [Abstract][Full Text] [Related]
8. Effect of BQ-123 and tissue plasminogen activator on vasospasm after subarachnoid hemorrhage in monkeys. Kim CJ; Bassiouny M; Macdonald RL; Weir B; Johns LM Stroke; 1996 Sep; 27(9):1629-33. PubMed ID: 8784140 [TBL] [Abstract][Full Text] [Related]
9. Effects of unilateral intrathecal administrations of low dose tissue-type plasminogen activator on clot lysis, vasospasm and brain phospholipid hydroperoxidation in a primate model of bilateral subarachnoid hemorrhage. Suzuki H; Kanamaru K; Kuroki M; Sun H; Waga S; Miyazawa T Neurol Res; 1998 Oct; 20(7):625-31. PubMed ID: 9785591 [TBL] [Abstract][Full Text] [Related]
10. A dosage study of the effect of the 21-aminosteroid U74006F on chronic cerebral vasospasm in a primate model. Kanamaru K; Weir BK; Findlay JM; Grace M; Macdonald RL Neurosurgery; 1990 Jul; 27(1):29-38. PubMed ID: 2377279 [TBL] [Abstract][Full Text] [Related]
11. The effect of timing of clot removal on chronic vasospasm in a primate model. Handa Y; Weir BK; Nosko M; Mosewich R; Tsuji T; Grace M J Neurosurg; 1987 Oct; 67(4):558-64. PubMed ID: 3655894 [TBL] [Abstract][Full Text] [Related]
12. Temporal changes in perivascular concentrations of oxyhemoglobin, deoxyhemoglobin, and methemoglobin after subarachnoid hemorrhage. Pluta RM; Afshar JK; Boock RJ; Oldfield EH J Neurosurg; 1998 Mar; 88(3):557-61. PubMed ID: 9488312 [TBL] [Abstract][Full Text] [Related]
13. [Preliminary clinical trial of intrathecal rt-PA (TD-2061) for the prevention of cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage]. Sasaki T; Ohta T; Kikuch H; Takakura K; Usui M; Kondoh A; Tanabe H; Nakamura J; Yamada K No To Shinkei; 1992 Nov; 44(11):1001-8. PubMed ID: 1296711 [TBL] [Abstract][Full Text] [Related]
14. Etiology of cerebral vasospasm in primates. Macdonald RL; Weir BK; Runzer TD; Grace MG; Findlay JM; Saito K; Cook DA; Mielke BW; Kanamaru K J Neurosurg; 1991 Sep; 75(3):415-24. PubMed ID: 1869943 [TBL] [Abstract][Full Text] [Related]
16. Effect of intrathecal superoxide dismutase and catalase on oxyhemoglobin-induced vasospasm in monkeys. Macdonald RL; Weir BK; Runzer TD; Grace MG; Poznansky MJ Neurosurgery; 1992 Apr; 30(4):529-39. PubMed ID: 1584351 [TBL] [Abstract][Full Text] [Related]
17. Thrombolytic therapy with tissue plasminogen activator for prevention of vasospasm in experimental subarachnoid hemorrhage: its efficacy and problems. Asada M; Kong J; Nakamura M; Tamaki N Neurol Res; 1996 Aug; 18(4):342-4. PubMed ID: 8875453 [TBL] [Abstract][Full Text] [Related]
18. A randomized trial of intraoperative, intracisternal tissue plasminogen activator for the prevention of vasospasm. Findlay JM; Kassell NF; Weir BK; Haley EC; Kongable G; Germanson T; Truskowski L; Alves WM; Holness RO; Knuckey NW Neurosurgery; 1995 Jul; 37(1):168-76; discussion 177-8. PubMed ID: 8587685 [TBL] [Abstract][Full Text] [Related]
19. Neuropeptide Y in the primate model of subarachnoid hemorrhage. Pluta RM; Deka-Starosta A; Zauner A; Morgan JK; Muraszko KM; Oldfield EH J Neurosurg; 1992 Sep; 77(3):417-23. PubMed ID: 1506889 [TBL] [Abstract][Full Text] [Related]
20. Effect of cyclosporine on the development of cerebral vasospasm in a primate model. Handa Y; Hayashi M; Takeuchi H; Kobayashi H; Kawano H; Kabuto M Neurosurgery; 1991 Mar; 28(3):380-5; discussion 385-6. PubMed ID: 2011219 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]